Showing results (141-150 of 212) with videos related to
Sort By:
Pageof 22
AIDS (London, England)|January 26, 2026
Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/mL and history of K103N mutationGraeme Moyle, Lambert Assoumou, Nathalie De Castro, et al.European Journal of Haematology|January 6, 2025
Impact of Day 11 Methotrexate Dose Adjustments due to Mucositis on the Outcomes Following Allogeneic Stem Cell Transplant in the Setting of Anti Thymocyte Globulin (ATG) Based GVHD ProphylaxisVinita Dhir, Connor Prince, David Allan, et al.European Journal of Haematology|July 9, 2024
Outcomes with low dose anti-thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantationHafsah Chalchal, Vinita Dhir, Ashish Masurekar, et al.AIDS Research and Therapy|March 22, 2024
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studiesSharon Walmsley, Don E Smith, Miguel Górgolas, et al.Acta Crystallographica. Section B, Structural Science|May 19, 2011
The effect of pressure on the crystal structure of bianthroneRussell D L Johnstone, David Allan, Alistair Lennie, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 19, 2017
Risk of Exposure to Zika Virus and Impact on Cord Blood Banking and Adult Unrelated Donors in Hematopoietic Cell Transplantation: The Canadian Blood Services ExperienceZachary Adams, Gail Morris, Todd Campbell, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 9, 2013
Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?Natasha Kekre, Melanie Tokessy, Ranjeeta Mallick, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 12, 2024
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196Stéphane De Wit, Fabrice Bonnet, Olayemi Osiyemi, et al.Transplantation and Cellular Therapy|February 14, 2026
Factors Associated with Prolonged Inpatient Stay in Patients undergoing Outpatient Allogeneic Stem Cell TransplantationEdward Koo, Connor Prince, David Allan, et al.AIDS and Behavior|September 3, 2024
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA StudyPrincy Kumar, Amanda E Clarke, Celia Jonsson-Oldenbüttel, et al.Pageof 22